MediPharm Labs AI Stock Analysis
MediPharm Labs (MLZ) AI Stock Analysis
MediPharm Labs
(Frankfurt:MLZ)
No summary available
MediPharm Labs (MLZ) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 20.08M
- Dividend Yield
- ―
- Average Volume (3M)
- 2,910
- Price to Earnings (P/E)
- -9.2
- Beta (1Y)
- -0.24
- Revenue Growth
- -13.17%
- EPS Growth
- 67.74%
- Country
- Germany
- Employees
- 127
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
MediPharm Labs Business Overview & Revenue Model
Company Description
MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across C...
MediPharm Labs Earnings Call Summary
The call was predominantly positive. MediPharm reported 18% sequential revenue growth, strong international medical performance, positive net income for the second consecutive quarter, positive adjusted EBITDA for the third consecutive quarter, lower operating expenses and a strong balance sheet. These achievements outweighed the stated challenges in Australia, the impact of Veterans Affairs Canada reimbursement changes, the year-to-date revenue decline versus the prior year and the sequential gross margin decrease.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said Australia’s recovery will take time, but the actions taken are believed to better align the portfolio with evolving patient demand and position the business for improved performance over time. The Q1 restructuring initiatives are expected to generate more than $1 million in annualized savings. MediPharm intends to continue expanding in regulated medical markets, pursue future commercialization of its metered dose inhaler in the U.K. and European Union, and evaluate selective M&A opportunities that meet its return thresholds. Brazil remains an attractive longer-term growth opportunity, while the LiBBY study may lead to potential additional clinical development or regulatory pathways and/or strategic partnerships.
MediPharm Labs Peers Comparison
Overall Rating
TSE:ROMJ58Neutral
TSE:INNO56Neutral
TSE:OILS43Neutral
TSE:AVCN42Neutral
TSE:PCLO39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 58Neutral | CAD 24.67M | -14.43 | -4.00% | ― | 16.91% | -244.25% | |
| 56Neutral | CAD 7.42M | -5.56 | -19.37% | ― | -19.20% | 42.54% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | CAD 4.26M | -2.19 | -43.92% | ― | -18.30% | -397.37% | |
| 42Neutral | CAD 12.09M | -4.09 | -65.40% | ― | -3.32% | -34.15% | |
| 39Underperform | CAD 9.34M | -2.67 | 28.59% | ― | 0.90% | 57.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:MLZ | Medipharm Labs (Otc) | 0.03 | -0.01 | -15.38% | |
| TSE:PCLO | Pharmacielo | 0.05 | 0.01 | 11.11% | |
| TSE:OILS | Nextleaf Solutions | 0.03 | -0.03 | -54.55% | |
| TSE:ROMJ | Rubicon Organics | 0.36 | -0.09 | -18.89% | |
| TSE:AVCN | Avicanna Inc | 0.09 | -0.15 | -63.27% | |
| TSE:INNO | Innocan Pharma Corporation | 1.65 | -14.05 | -89.49% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
